
Dana Sarnak, PhD, and Wen Shen, MD, on trends in menopause hormone therapy
Key Takeaways
- In a Johns Hopkins analysis of 103,488 patients, the MHT prescription rate rose from 18 to 28 per 1,000 patients through 2024 to 61 per 1,000 in Q1 2026, with the sharpest increases among women aged 45 to 59.
- Prescribing was already climbing before the FDA lifted the MHT black box warning in November 2025, driven by greater recognition of women’s health, patient demand, and menopause coverage in social and traditional media.
Dana Sarnak, PhD, and Wen Shen, MD, comment on a Johns Hopkins analysis showing rising menopause hormone therapy use among midlife women.
Menopause hormone therapy (MHT) prescribing has risen substantially among midlife women, according to an analysis of Johns Hopkins Health System electronic medical record data presented by Dana Sarnak, PhD, of Johns Hopkins University in Baltimore, Maryland, and Wen Shen, MD, MPH, of the Department of Gynecology and Obstetrics at Johns Hopkins University. The pair discussed the findings in an interview at
Rising MHT prescribing at Johns Hopkins
The analysis included 103,488 female patients aged 40 to 69 seen in gynecology and obstetrics across the health system from 2016 through the first quarter of 2026.1 The absolute number of distinct MHT orders per quarter rose from 176 in the first quarter of 2016 to 469 in the first quarter of 2025 and 840 in the first quarter of 2026.1
The MHT prescription rate, defined as distinct orders per 1000 patients, held between 18 and 28 through the end of 2024, then climbed from 35 to 50 across 2025 and reached 61 in the first quarter of 2026, with the sharpest increases among women aged 45 to 59.1
Utilization at Hopkins was very low until around 2022, consistent with national data, Sarnak said, before prescribing of vaginal estrogen, progestogen products, and transdermal estrogen began to rise, with a steeper increase around January 2024.
“Those were increasing up to the FDA landmark decision in November 2025,” Sarnak said, noting that because the Hopkins data ran only through January 2026, the analysis could not fully assess the effect of the regulatory change, though she was confident prescribing had changed leading up to it.
What is driving the increase?
Shen attributed the shift to a broader recognition of women’s health as distinct from men’s health. For years, she noted, NIH research enrolled mainly male participants, and even bench research used male animals, leaving women’s health poorly understood. She credited figures including the late Bernadine Healy, MD, a Johns Hopkins cardiologist who led the NIH and championed women’s health research, along with advocacy from former first ladies.
Sarnak added that growing menopause coverage in social and traditional media has also likely amplified those forces, prompting patients to ask for treatment and encouraging clinicians to learn about their options. The study examined prescribing data rather than medications dispensed or picked up, she noted.
The limits of WHI-era evidence
Much of the evidence still used to guide hormone therapy comes from the Women’s Health Initiative (WHI), which studied women at an average age of 65 and does not translate well to a woman entering the menopause transition around age 50, Shen said. The WHI found that women more than 10 years past their final menstrual period who took oral conjugated equine estrogen and medroxyprogesterone acetate had an increased risk of cardiovascular events, and there is now a push for better data on the timing hypothesis.
“So much has changed since then,” Shen said, expressing hope that stronger evidence will allow recommendations to be tailored, which she said would be meaningful for the generation of women who came of age just after the WHI and feel they missed out.
Reference:
Sarnak D, Shen W, et al. Contemporary trends in menopause hormone therapy. Presented at: The Menopause Society Annual Meeting. October 20-24, 2026. San Diego, California.
Related to this article








